AQST Aquestive Therapeutics Inc
Company Analysis
Latest News
🔴 Aquestive Therapeutics is trading 9.1% down in pre-market with no company-specific explanation identified
Aquestive Therapeutics is trading 9.1% lower at $3.71 in pre-market on October 22, with no company-specific announcement identified to explain the decline;...
🟢 Aquestive Therapeutics is trading 5% up today with biotech shares higher
Aquestive Therapeutics is trading at $4.04, up 5.35%, with biotech-sector strength providing supportive context; the cause of today’s move is unconfirmed. - No...
Aquestive Gets a Second Shot at an Allergy Breakthrough — But Can a $500 Million Company Fund the Launch It Needs?
Shares of Aquestive Therapeutics surged +11.1% to $4.20 after the FDA accepted the company's resubmitted application for its under-the-tongue epinephrine film...
🟢 Aquestive Therapeutics is trading 11.11% up in pre-market after FDA accepts Anaphylm NDA resubmission as complete
Aquestive Therapeutics is trading at $4.20 (+11.11%) in pre-market after the FDA accepted the Anaphylm NDA resubmission as complete. - The company announced...
Aquestive Gains FDA Review for Anaphylm, the First Oral Allergy Film
Aquestive Therapeutics announced the FDA accepted its resubmitted New Drug Application for Anaphylm. The agency classified the sublingual film for severe...
🔴 Aquestive Therapeutics is trading 5.54% down with no clear company-specific catalyst
Aquestive Therapeutics is trading 5.54% lower at $3.83, with no clear company-specific news explaining the decline. - The biotech ETF XBI is down 2.06%, while...
🔴 Aquestive Therapeutics is trading 10.1% down with no clear catalyst identified
Aquestive Therapeutics is trading 10.1% down now at $4.14 on October 15, 2026, with no clear company-specific catalyst identified for the decline. - The...
🔴 Aquestive Therapeutics is trading 6.2% down; reason remains unclear
Aquestive Therapeutics is trading at $4.33, 6.2% down on October 15, 2026; available reporting does not identify a cause for the intraday decline. - The...
Aquestive Announces FDA Acceptance of Anaphylm™ NDA and Sets March 2027 PDUFA Date
Aquestive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for Anaphylm™...
Aquestive Licenses U.S. Rights for LIBERVANT to Eton Pharma in $57.5M Deal
Aquestive Therapeutics, Inc. (AQST) has entered into an exclusive license agreement with Eton Pharmaceuticals, Inc. (Eton) for the U.S. commercialization of...
Aquestive Therapeutics Resubmits NDA to FDA for Anaphylm Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, Anaphylm...
🟢 Aquestive Therapeutics rises 5.0% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
Aquestive Resubmits New Drug Application to FDA for Anaphylm™ Sublingual Film
Aquestive Therapeutics announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™...
Aquestive Resubmits Anaphylm NDA, Slashing Emergency Opening Time to 3 Seconds
Aquestive Therapeutics resubmitted its New Drug Application (NDA) to the FDA for Anaphylm. This under-the-tongue film treats severe allergic reactions,...
🟢 Aquestive Therapeutics is trading 5% up in pre-market as Nasdaq Composite gains 0.52%
Aquestive Therapeutics is trading at $5.07, up 5.48%, with the move appearing aligned with a firm pre-market backdrop. - No new company-specific announcement...
🟢 Aquestive Therapeutics is trading 5% up today amid biotech-sector momentum
Aquestive Therapeutics is trading 5% up now at $5.33, with biotech-sector momentum appearing to drive the move. - Biotech ETF XBI rose 2.06% during regular...
🟢 Aquestive Therapeutics rises 5.1% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Aquestive Therapeutics is trading 8.9% up today as biotech shares rally on Moderna trial results
Aquestive Therapeutics is trading 8.9% up at $4.71, outperforming its recent closes as biotechnology shares rally on positive Moderna cancer-vaccine trial...
🟢 Aquestive Therapeutics is trading 5.88% up in pre-market with no clear catalyst identified
Aquestive Therapeutics is trading 5.88% up in pre-market at $4.50, versus the August 14, 2026 close of $4.25; no new company-specific announcement explaining...
🔴 Aquestive Therapeutics is trading 5% down today after wider-than-expected Q2 loss
Aquestive Therapeutics is trading 5% down now at $4.04 after investors continued weighing its August 11 earnings. - Second-quarter revenue increased 38% year...